Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2013-07-25FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for Keppra (levetiracetam) submitted by UCB, Inc., authorizing changes to the drug's labeling.
-
FDA approval · 2013-07-25FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for KEPPRA (levetiracetam) submitted by UCB, Inc.
-
FDA label_change · 2013-07-25FDA Approved: TOPAMAX — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for TOPAMAX (topiramate) filed by Janssen Pharmaceuticals, Inc. The approval updates the labelin…
-
FDA approval · 2013-07-25FDA Approved: KEPPRA XR — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for KEPPRA XR (levetiracetam) submitted by UCB, Inc.
-
FDA approval · 2013-07-15FDA Approved: LAMOTRIGINE — Original Application (Amneal Pharmaceuticals of New York LLC)
The FDA approved Amneal Pharmaceuticals of New York LLC's original ANDA for lamotrigine, a generic version of the anticonvulsant. The approv…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2013-07-12Clinical Trial Update: A Study in Stable Epilepsy Patients Comparing Brand and Generic Divalproex Sodium Extended Release Tablets [Phase 1]
Phase 1 clinical trial update comparing brand-name Depakote ER with generic divalproex sodium extended-release tablets in stable epilepsy pa…
-
FDA approval · 2013-07-12FDA Approved: GABAPENTIN — Original Application (ACI Healthcare USA, Inc.)
FDA approved a generic gabapentin product under an Original Application filed by ACI Healthcare USA, Inc.
-
FDA approval · 2013-07-09FDA Approved: EPITOL — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for EPITOL (carbamazepine) filed by Teva Pharmaceuticals USA, Inc., under ANDA070541.
-
CLINICAL_TRIALS research · 2013-07-04Clinical Trial Update: The Clinical Application and Mechanism of Music Therapy (Mozart's Effect) on Epilepsy [NA]
A completed clinical trial from Kaohsiung Medical University Chung-Ho Memorial Hospital investigating music therapy (Mozart's effect) as a t…
-
FDA approval · 2013-06-30FDA Approved: FYCOMPA — Supplemental Application (Eisai Inc.)
The FDA approved Eisai's supplemental application for FYCOMPA (perampanel), resulting in changes to the product labeling.
-
FDA approval · 2013-06-26FDA Approved: LEVETIRACETAM — Original Application (Sagent Pharmaceuticals)
FDA approves the original application for a generic levetiracetam product from Sagent Pharmaceuticals.
-
CLINICAL_TRIALS research · 2013-06-26Clinical Trial Update: A Cross-sectional Study to Investigate the Effect of Topiramate on Bone and Mineral Metabolism in Female Participants With Epilepsy
This completed cross-sectional study in female participants with epilepsy examines the effect of topiramate on bone and mineral metabolism, …
-
FDA approval · 2013-06-19FDA Approved: LAMOTRIGINE — Original Application (NorthStar Rx LLC)
FDA approved NorthStar Rx LLC's generic Lamotrigine under an Original Application (ANDA) for use in treating epilepsy and bipolar disorder.
-
CLINICAL_TRIALS trial_result · 2013-06-18Clinical Trial Update: An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures [Phase 3]
An open-label extension of a Phase 3 study evaluating the safety and tolerability of add-on carisbamate in patients with partial-onset seizu…
-
CLINICAL_TRIALS trial_result · 2013-06-18Clinical Trial Update: An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures. [Phase 3]
An open-label extension study in adults (16 years and older) with partial-onset seizures evaluated the safety and tolerability of RWJ 333369…
-
FDA label_change · 2013-06-14FDA Approved: DEPAKOTE — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for Depakote (divalproex sodium) submitted by AbbVie, resulting in labeling changes for the prod…
-
FDA approval · 2013-06-14FDA Approved: DEPAKOTE ER — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for DEPAKOTE ER (divalproex sodium) submitted by AbbVie Inc.
-
FDA approval · 2013-06-14FDA Approved: OXTELLAR XR — Supplemental Application (Supernus Pharmaceuticals, Inc.)
The FDA approved a supplemental application for OXTELLAR XR (oxcarbazepine) from Supernus Pharmaceuticals, indicating regulatory approval to…
-
FDA approval · 2013-06-14FDA Approved: LAMOTRIGINE — Original Application (Ascend Laboratories, LLC)
FDA approves Ascend Laboratories, LLC's original ANDA for lamotrigine, enabling the marketing of a lamotrigine generic product.
-
FDA approval · 2013-06-13FDA Approved: CARBAMAZEPINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for carbamazepine from Sun Pharmaceutical Industries, Inc., indicating an update to the product's re…
-
FDA approval · 2013-06-13FDA Approved: CARBAMAZEPINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for carbamazepine submitted by Sun Pharmaceutical Industries, Inc.
-
CLINICAL_TRIALS trial_result · 2013-06-04Clinical Trial Update: Prevention of Photoparoxysmal Abnormalities by Mozart K448 [NA]
This clinical trial evaluating prevention of photoparoxysmal abnormalities by Mozart K448 in people with epilepsy and seizures was terminate…
-
CLINICAL_TRIALS trial_result · 2013-06-03Clinical Trial Update: External Trigeminal Nerve Stimulation for Epilepsy [Phase 2]
A Phase 2 clinical trial evaluating external trigeminal nerve stimulation for epilepsy has completed and results were posted.
-
FDA approval · 2013-05-31FDA Approved: CLONAZEPAM — Supplemental Application (Advagen Pharma Ltd)
FDA approved Advagen Pharma Ltd's supplemental application for clonazepam (generic) under ANDA075468, authorizing an additional clonazepam p…
-
CLINICAL_TRIALS trial_result · 2013-05-24Clinical Trial Update: First Add-on vs. Mono-therapy Study of Topiramate in Neuro-Surgical Patients [Phase 4]
A Phase 4 trial comparing add-on versus monotherapy Topiramate in epilepsy patients undergoing neurosurgery; results were posted in 2013.